Small cell lung cancer (SCLC) is the less-common type of lung cancer, accounting for about 15 percent of lung cancer cases. SCLC is the most aggressive and fastest spreading form of all lung cancers.

The treatment marks the only targeted oral treatment in patients with non–small cell lung cancer with epidermal growth factor ...

Corticosteroids, a commonly prescribed medication to alleviate cancer-related symptoms for non-small cell lung cancer ...

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...

Indeed, germline TP53 and EGFR mutations are associated with early-onset lung tumors. 76, 77 However, rare variants such as BRCA K3326* (OR, 2.1 for small cell lung cancer and OR, 1.7 for squamous ...

A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery ...

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

SCLC incidence in the US is projected to decline significantly through 2050, continuing a trend from 2000 to 2021. The study ...

The FDA has granted accelerated approval to datopotamab deruxtecan (Datroway) for adults with locally advanced or metastatic non-small cell lung cancer that carries an EGFR mutation and has progressed ...

When celebrated actor, Natthawut "Poh" Skidjai, revealed on his YouTube channel @PohSakidAey that his wife Aey Pornthip had ...